Trials / Completed
CompletedNCT02135510
MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy
MEtoclopramide, DExamethasone or Axoli (Palonoseton) for the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy: the MEDEA-trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 249 (actual)
- Sponsor
- Amsterdam UMC, location VUmc · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this phase III non-inferiority trial, the aim is to evaluate whether metoclopramide and palonosetron prophylactic antemetic treatment are non-inferior to dexamethasone with regard to its efficacy to prevent delayed chemotherapy-induced nausea and vomiting (CINV) induced by non- anthracyclines plus cyclophosphamide (AC) based moderately emetogenic chemotherapy (MEC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | metoclopramide | |
| DRUG | dexamethason | |
| DRUG | palonosetron |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2019-03-01
- Completion
- 2019-03-01
- First posted
- 2014-05-12
- Last updated
- 2020-03-31
Locations
7 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02135510. Inclusion in this directory is not an endorsement.